

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

Monoclonal Anti-Vinculin antibody produced in mouse

RRID:AB_477617

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# V4505, RRID:AB_477617

Antibody Information

URL: http://antibodyregistry.org/AB_477617

Proper Citation: Sigma-Aldrich Cat# V4505, RRID:AB_477617

Target Antigen: Vinculin antibody produced in mouse

Host Organism: mouse

Clonality: monoclonal

Comments: Vendor recommendations: IgG1 Other; Western Blot; Immunofluorescence; microarray: suitable, immunoblotting: suitable, indirect immunofluorescence: 1:50

Antibody Name: Monoclonal Anti-Vinculin antibody produced in mouse

Description: This monoclonal targets Vinculin antibody produced in mouse

Target Organism: chicken, mouse, chickenbird, bovine, human

Antibody ID: AB_477617

Vendor: Sigma-Aldrich

Catalog Number: V4505

Record Creation Time: 20250819T204843+0000

Record Last Update: 20250819T205401+0000

Ratings and Alerts

No rating or validation information has been found for Monoclonal Anti-Vinculin antibody produced in mouse.

No alerts have been found for Monoclonal Anti-Vinculin antibody produced in mouse.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. *Cancer cell*.

Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. *Cell reports*, 44(10), 116433.

Ho-Xuan H, et al. (2025) YTHDF proteins and m6A-RNA clients undergo autophagic turnover during contact inhibition. *Cell reports*, 44(9), 116188.

Lei G, et al. (2025) Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. *Cancer cell*, 43(6), 1076.

Lavanderos B, et al. (2025) Rhotekin-1 is a novel interacting protein and regulator of TRPC6 activity. *The FEBS journal*, 292(16), 4353.

Yu H, et al. (2025) Energy status orchestrates YTHDF1 phase separation and tumorigenesis. *Cell reports*, 44(11), 116466.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. *Nature communications*, 16(1), 512.

Madej M, et al. (2025) PUS10-induced tRNA fragmentation impacts retrotransposon-driven inflammation. *Cell reports*, 44(6), 115735.

Mao C, et al. (2024) Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers. *Molecular cell*, 84(10), 1964.

Brock K, et al. (2024) A comparative analysis of paxillin and Hic-5 proximity interactomes. *Cytoskeleton (Hoboken, N.J.)*.

Ryu JE, et al. (2024) Circadian regulation of endoplasmic reticulum calcium response in cultured mouse astrocytes. *eLife*, 13.

Hao M, et al. (2024) In vivo CRISPR knockout screen identifies p47 as a suppressor of HER2+ breast cancer metastasis by regulating NEMO trafficking and autophagy flux. *Cell reports*, 43(2), 113780.

Martin Flores N, et al. (2024) Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model. *eLife*, 12.

Tábara LC, et al. (2024) MTFP1 controls mitochondrial fusion to regulate inner membrane quality control and maintain mtDNA levels. *Cell*, 187(14), 3619.

Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. *EBioMedicine*, 105, 105212.

Tam KJ, et al. (2024) Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. *Scientific reports*, 14(1), 7082.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Chen M, et al. (2023) Identification of XAF1 as an endogenous AKT inhibitor. *Cell reports*, 42(7), 112690.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Jones ME, et al. (2023) A genetic variant of the Wnt receptor LRP6 accelerates synapse degeneration during aging and in Alzheimer's disease. *Science advances*, 9(2), eabo7421.